Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study-Reference-Cited by-同舟云学术

Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study

Published:2017-11-25 Issue:2 Volume:37 Page:305-311
ISSN:0934-9723
Container-title:European Journal of Clinical Microbiology & Infectious Diseases
language:en
Short-container-title:Eur J Clin Microbiol Infect Dis

Author:

Ko J.-H.,Lee N. R.,Joo E.-J.,Moon S.-y.,Choi J.-K.,Park D. A.,Peck K. R.

Funder

National Evidence-based Healthcare Collaborating Agency (KR)

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Link

http://link.springer.com/article/10.1007/s10096-017-3133-2/fulltext.html

Reference34 articles.

1. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA (2007) Comparative review of the carbapenems. Drugs 67:1027–1052

2. Rupp ME, Fey PD (2003) Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs 63:353–365

3. Canton R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, Coque TM (2008) Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect 14(Suppl 1):144–153. https://doi.org/10.1111/j.1469-0691.2007.01850.x

4. Sheng WH, Badal RE, Hsueh PR (2013) Distribution of extended-spectrum beta-lactamases, AmpC beta-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for monitoring antimicrobial resistance trends (SMART). Antimicrob Agents Chemother 57:2981–2988. https://doi.org/10.1128/aac.00971-12

5. Pitout JD, Nordmann P, Laupland KB, Poirel L (2005) Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 56:52–59. https://doi.org/10.1093/jac/dki166

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing Enterobacterales bloodstream infections: A systematic review and meta-analysis;Journal of Global Antimicrobial Resistance;2024-12

2. Bloodstream infections due to multi-drug resistant bacteria in the emergency department: prevalence, risk factors and outcomes—a retrospective observational study;Internal and Emergency Medicine;2024-07-13

3. No improvement in mortality among critically ill patients with carbapenems as initial empirical therapy and more detection of multi-drug resistant pathogens associated with longer use: a post hoc analysis of a prospective cohort study;Microbiology Spectrum;2024-07-02

4. Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP;Antibiotics;2024-03-25

5. Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin–Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing Enterobacterales Secondary Bloodstream Infections: Findings from a Prospective Pilot Study;Microorganisms;2024-01-12